ANIX

Insider Trades

Name	Value	Action	Price	Current Price
Baskies Arnold MDirector $30k10k shares BuyJan 28, 2026 $3.04 --
Titterton Lewis H jrDirector $31k10k shares BuyJul 31, 2025 $3.08 --
Kumar AmitChief Executive Officer $16k5k shares BuyJul 30, 2025 $3.16 --
Baskies Arnold MDirector $17k5k shares BuyJul 18, 2025 $3.39 --
Titterton Lewis H jrDirector $31k10k shares BuyJul 11, 2025 $3.14 --
Kumar AmitChief Executive Officer $16k5k shares BuyJul 11, 2025 $3.15 --

News

prnewswire.comAnixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposiumprnewswire.comJun 11

prnewswire.comAnixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowanceprnewswire.comJun 1

prnewswire.comAnixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapyprnewswire.comMay 11

prnewswire.comAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TVprnewswire.comMay 1

prnewswire.comAnixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technologyprnewswire.comApr 29

Trade ANIX

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.

CEO: Amit Kumar
IPO Date: Oct 7, 1983

Market Data

Open: $2.76
High: $2.93
Low: $2.60
Volume: 585.2K
Avg Volume: 128.8K
52W High: $5.46
52W Low: $2.32

Valuation

Market Cap: $99M
Enterprise Value: $98M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-7.2M
Revenue: $0
Net Income: $-11M
Cash: $1.2M
Debt: $204k

Events

EarningsSep 10

EPS est. -0.08